Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models.
Jian L CampianSubhajit GhoshVaishali KapoorRan YanSukrutha ThotalaArijita JashTong HuAnita MahadevanKasem RifaiLogan PageByung Ha LeeSara Ferrando-MartinezAlexandra A WolfarthSe Hwan YangDennis HallahanMilan G ChhedaDinesh ThotalaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
In orthotopic glioma-bearing mice, NT-I7 mitigates RT-related lymphopenia, increases cytotoxic CD8 T lymphocytes systemically and in the tumor, and improves survival. A phase I/II trial to evaluate NT-I7 in patients with high-grade gliomas is ongoing (NCT03687957).